ONE HEALTH DR. Theo Kanellos Director, Strategic Alliances Zoetis International Services.

Slides:



Advertisements
Similar presentations
1 Increasing Biotech Involvement in Global Health Innovation Oxford Conference on Innovation and Technology Transfer for Global Health September 11, 2007.
Advertisements

Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.
Steven D. Vaughn, DVM Director Office of New Animal Drug Evaluation Center for Veterinary Medicine U. S. Food and Drug Administration June 6, 2012 Embracing.
Alternative Careers in Pharma and Biotechnology Douglas Buckley Ph.D. May 13, 2011 Alternative Career Symposium Baylor College of Medicine.
GASP Vision The Georgia Association of Sleep Professionals is the leader in Georgia for setting standards and promoting excellence in sleep medicine care,
Global African Swine Fever Research Alliance Fighting African Swine Fever Together Cyril G. Gay, DVM, PhD Senior National Program Leader Animal Production.
Linking BRICS innovation potential through Innovation Networking Platform Sergey Korotkov Director, UNIDO CIIC Russia.
Storyboard Presentation – Enabling Tools February 20-21, 2007 / St. Pete’s Beach, FL Sean Osborne (248) Director,
About Us life diagnostica is an innovative company that develops strategic business alliances with foreign companies who wish to tap into the huge Indian.
Medical Tourism in Jordan Prepared by: Dr. Ratib Hinnawi (MOH Advisor) Ministry of Health – Jordan 2007.
Medical Diagnostics NIAID Funding Opportunities Maria Y. Giovanni, Ph.D. Assistant Director for Microbial Genomics and Advanced Technologies National Institute.
Global Vaccines 202X : Access, Equity, Ethics Panel discussion: Pandemic Influenza Preparedness Framework for the sharing of Influenza Viruses and Access.
Introduction Opportunity Market potential of recombinant drugs Problem Lack of manufacturing capacity Solution PharmOut: Contract BioManufacturing.
Avian Influenza H5N1 Reactive Antibodies BA 468x Technology Commercialization.
SUCCESS FACTORS IN THE PHARMACEUTICAL MARKETPLACE
OIC-SHPA & Vaccines Need Assessment in OIC Member Countries
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
The NIH Roadmap for Medical Research
The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.
Custom Synthesis (R&D and cGMP)| Commercialization Expertise |Consulting Services.
Towards a global plan to fight against bioterrorism in synergy with Russian Federation Novosibirsk
FORESIGHT STUDY Future Trends and Challenges in Pathogenomics JUDITH SIMON & SVEN POMPE PROGRAMME GROUP MUT.
Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.
THANK YOU!. Regional Adviser, Noncommunicable Diseases, WHO/EMRO Dr Ibtihal Fadhil.
Innovation Pathway AHSN Stakeholder Event Russ Watkins Assistant Director – Business Innovation & Improvement Newcastle Hospitals.
BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Solving the Missing Link Between Forecasting and ERP in Clinical Supply Optimization Michelle.
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
Company Overview NZFMA Seminar March 2013
Managing Medical R&D Defining and Realizing Clinical and Commercial Value David J. Wierz Senior Director Commercial Investment & Pricing Strategy Wyeth-Ayerst.
To Fight EID, Think Global, Act Local Our response to Emerging Diseases is considered on a global basis, but implementation is regional – The risk and.
TB PUBLIC-PRIVATE MIX DOTS Dr. Team Bakkhim Deputy Director CENAT Intercontinental Hotel 7 th November, 2012 NATIONAL FORUM ON PUBLIC-PRIVATE PARTNERSHIP.
September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.
DRAFT V1 National Vaccine Supply Chain Innovations: Country Commitment to Ownership, Sustainability & Impact GAVI Partners’ Forum WHO – UNICEF – GAVI -
WIPO Pilot Project - Assisting Member States to Create an Adequate Innovation Infrastructure to Support University – Industry Collaboration.
Clinical trials in Framework programme 7 (FP7) EU Judita Kinkorová 2. Národní konference o doporučených postupech, Olomouc 13. listopadu 2010.
TruSuccess Business Solutions January 1, © 2007 TruSuccess Advisory 2 Outline  Overview of TruSuccess Business Solutions  Business Analytics solutions.
Strategy and Policy Cohesion: “The One Health Agenda: will it deliver” Elizabeth J. Phillips, MD, FRCPC,FRACP, FACTM Professor & Director, Centre for Clinical.
PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model.
Global Vaccines 202X: Access, Equity, Ethics Novartis Vaccines & Diagnostics Clement Lewin PhD MBA Head Medical Affairs & Policy Region North America Philadelphia;
ISPE Central Canada Chapter Annual Meeting September 28, 2006 Yvon R. Tessier Pharmaceutical contract manufacturing challenges.
Enter Title of Presentation on Master Slide U.S. Department of Health and Human Services Office of the Assistant Secretary for Public Health Emergency.
Consortium for Interdisciplinary Studies on Science for Aging.
NEACS: CRO Perspective William Feher Vice President, Internal Audit and Chief Risk Officer October 27, 2015.
Establishing a Global Vaccine Development Fund Peter Hale The Foundation for Vaccine Research Washington, DC Consultation on Financing of R&D Preparedness.
Project funded by the Spanish Ministry of Science and Innovation and the European Regional Development Fund PROGRESS REPORT SEPTEMBER 2009 Brussels, 22.
MDIC/Xavier University Device Product Quality Metrics December 8, 2015.
Laurie E. Locascio, Ph.D. Director, MML/NIST NIST/MML: Measurement Assurance for Biological Systems.
Medic Mobile. Improve health in underserved communities. Mission.
| Onderstepoort Biological Products © |22nd February 2013Page 1 Presentation to the Portfolio Committee on Agriculture, Forestry and 22 nd February 2013.
Emerging Threats Program Text The Emerging Pandemic Threats Program.
Roadmap Economic Impact & Funding Opportunities Dr Stephen Hillier
OVERVIEW OF THE WORKFORCE DEVELOPMENT DOMAIN TASK FORCE APRIL 16, 2015 Joan D. Nagel, M.D., M.P.H. Program Director, Division of Clinical Innovation National.
A European Academic Network for Vaccine Research An Idea from the Danish Mirror Group under ETPGAH Working group: Jens Kjær – Boehringer Ingelheim DK Poul.
One Health meeting Day one summary report Rapporteurs Cameroon and Uganda 12 Nov 2012.
1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.
Vaccine Company Perspective Dr Gaurav Gupta, ZYDUS CADILA
MICROBIAL HEALTH ECONOMY
CDRH 2010 Strategic Priorities
A Centre for New Methods in Computational Diagnostics and Personalised Therapy This EU H2020 ‘Teaming for Excellence’ project develops a Business Case.
Accessing Medicines in Africa Prospects and challenges
World Health Organization
World Health Organization
Introduction to TransCelerate
Clinical and Translational Science Awards Program
Strategy and Policy Cohesion: “The One Health Agenda: will it deliver”
Elanco Animal Health Partnering for Growth Bruce E. Taillon, PhD.
MAZARS’ CONSULTING PRACTICE
STRATEGIC ACTION IN HEALTH (AES)
Meet the JAKs.
Presentation transcript:

ONE HEALTH DR. Theo Kanellos Director, Strategic Alliances Zoetis International Services

ZOETIS: AN ADVOCATE OF ONE HEALTH 27 8 4.8+ $ CORE ANIMAL SPECIES MANUFACTURING SITES 300+ BILLION PRODUCT LINES SALES 1,100+ R&D COLLEAGUES WE PROVIDE MEDICINES VACCINES DIAGNOSTICS GENETIC TESTS SERVICES 5 60+ MAJOR PRODUCT CATEGORIES YEARS OF EXPERIENCE OUR FOCUS 120+ MARKET PRESENCE IN 34%1 APPROXIMATE COLLEAGUES AROUND THE WORLD 10,000 65%1 3,500+ MEMBER ZOETIS FIELD FORCE COMPANION ANIMAL HEALTH LIVESTOCK HEALTH 1Excludes revenue associated with Client Supply Services, which represented 1% of total 2014 revenue. COUNTRIES

DISEASE KNOWS NO BOUNDARIES

WHY IS ONE HEALTH IMPORTANT? COST OF CONTROL OUTBREAK EXPOSURE IN ANIMALS CLINICAL SIGNS IN ANIMALS EXPOSURE IN HUMANS CLINICAL SIGNS IN HUMANS HUMANS SEEK MEDICAL CARE Adapted from Institute Of Medicine (2009)

TIMEFRAME OF PRODUCT DEVELOPMENT HUMAN HEALTH PROJECT LIFECYCLE* 3-6 Years 6-7 Years 0.5-2 Years Discovery/Preclinical Phase One Phase Two Phase Three Approval Process First in Human Decision ANIMAL HEALTH PROJECT LIFECYCLE : KEY DIFFERENTIATORS Feasibility in target species understood early in project lifecycle Shorter duration for field trials Process scale-up and transfer to manufacturing generally drives development timeline PhRMA, 2009

First industry partner to receive USDA approval for H1N1 vaccine SUCCESS OF ONE HEALTH APPROACH RAPID DEVELOPMENT OF H1N1 VACCINE FOR SWINE  First industry partner to receive USDA approval for H1N1 vaccine Developed vaccine in a record 4-month period Scientific Development Manufacturing Scale-up Regulatory Approvals A ONE TEAM approach with USDA Prudent risk-taking & innovations Strain selection, parallel efforts in scale-up and clinical studies Manufacture of extensive supplies before market needs were fully defined, Bioreactor, lyophilization cycle Zoetis’ INOVOJECT has been used in the manufacturing of human flu vaccines 1 2 3 4 5

SUCCESS OF ONE HEALTH APPROACH JAK INHIBITORS: TOFACITINIB / OCLACITINIB HUMANS ANIMALS (DOGS) Pfizer pioneered janus kinase inhibitors In 2012, Xeljanz (tofacitinib) was approved in the US for rheumatoid arthritis, the first of a new class of kinase inhibitors that inhibit intracellular signaling pathways triggered by cytokines In 2013, Zoetis, launched APOQUEL® (oclacitinib), a New Veterinary Class Targeting the Itch and Inflammation Pathway in dogs Oclacitinib (JAK-1) came from the same program that yielded tofacitinib ~10% of dogs have atopic dermatitis that can impact the quality of life for the dog and its owner JAK enzymes are involved in cell signalling pathways activated by various cytokines APOQUEL® reduces itch, and provides long term relief of itching and inflammation for dogs

EFPIA’s “PARTNERS IN RESEARCH” COULD FOSTER “ONE HEALTH” INNOVATIONS To Advance Impactful Solutions to Control Common Animal and Human Diseases by: Co-supporting the rapid development of technologies to prevent and control emerging and re-emerging pathogens Implementing holistic control strategies for zoonotic diseases mainly in developing countries To Enhance Innovative Research on Diseases with Common Pathophysiology by: Implementing novel One Health translational research models Developing the necessary capacities for ‘One Health’ research Launching targeted One Health research calls To Spark New Business Models to Augment Commercialization of Innovation by: Utilising Animal Health as a fast platform for new biotechnology products and diagnostics Establishing clinical development and regulatory synergies between R&D pipelines Interspersing expertise, research tools and resources to enhance R&D pipelines

A strategic forum for the continuation of the One Health debate

Thank you